Article thumbnail
Location of Repository

A review of the use of exemestane in early breast cancer

By Andrew Robinson

Abstract

Exemestane is a third-generation aromatase inhibitor, which has proven to be a useful drug in the treatment of early stage breast cancer. Several clinical trials have been performed or are currently underway using exemestane as adjuvant therapy in postmenopausal women, which will be the indication reviewed here. A relative reduction in risk of breast cancer recurrence or death of 24% has been shown with exemestane compared with tamoxifen when given after 2 to 3 years of tamoxifen. This corresponded to a 3.3% absolute reduction in recurrence or death at the end of 5 years, for a number needed to treat of 30. The main use of exemestane in the adjuvant setting is as an alternative to tamoxifen, and toxicities are discussed in relation to tamoxifen toxicities. In general, patients receiving exemestane experience less hot flashes and more arthralgias in comparison to tamoxifen, while there is also a reduction in venous thromboembolic events and vaginal bleeding. Patients on exemestane as a group do not appear to have a significantly changed quality of life in comparison to tamoxifen, while having a statistically significant benefit in preventing breast cancer recurrence

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2697518
Provided by: PubMed Central

Suggested articles

Citations

  1. A randomized trial of exemestane after two to three years of tamoxifen therapy in post-menopausal women with primary breast cancer.
  2. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
  3. Adjuvant endocrine therapy for premenopausal women with early breast cancer.
  4. Adrenalectomy and oophorectomy in treatment of advanced carcinoma of the breast.
  5. (2007). Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer.
  6. Benefi t from exemestane as extended adjuvant therapy following fi ve years of adjuvant tamoxifen:
  7. (2007). Bone health in postmenopausal women with early breast cancer: how protective is tamoxifen? Cancer Treat Rev.
  8. Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
  9. (2006). Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol.
  10. (2008). clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients. Drug Saf.
  11. Comparison of menopausal symptoms during the fi rst year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.
  12. (2006). Effect of hormone therapy on risk of hip and knee joint replacement in the Women’s Health Initiative. Arthritis Rheum.
  13. (1995). Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.
  14. Epidemiology and outcomes of osteoporotic fractures.
  15. (2008). Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. Breast Cancer Res Treat.
  16. Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials. Clin Breast Cancer. 2006;6 suppl 2:S41–S44.
  17. (2007). Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial. Anticancer Res.
  18. (2000). Exemestane as neoadjuvant treatment for locally advanced breast cancer: endocrinologic and clinical endpoints. Breast Cancer Res Treat.
  19. (2007). Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). Breast Cancer Res Treat.
  20. (2000). Exemestane for advanced breast cancer. Med Lett Drugs Ther.
  21. (2002). Global Cancer Statistics,
  22. (2004). Hip fracture prevention in postmenopausal women. Obstet Gynecol Surv.
  23. (2002). Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res Treat.
  24. (2007). Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol.
  25. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol. 2007;14 Suppl 1:S20–S40.
  26. (2008). Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptorpositive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03). Breast Cancer Res Treat.
  27. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases.
  28. (1999). Pharmacokinetics (PK) of Aromasin (Exemestane, EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV).
  29. (2008). Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol.
  30. Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
  31. (2008). Recognition and management of treatmentrelated side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat.
  32. (2007). Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol.
  33. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
  34. Switching to letrozole or exemestane improves hot fl ushes, mood and quality of life in tamoxifen intolerant women.
  35. (1998). Tamoxifen for prevention of breast cancer: report of the
  36. (2008). Tamoxifen use and osteoporotic fracture risk - A population based analysis. J Clin Oncol.
  37. The effect of exemestane on the lipidemic profi le of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
  38. (2008). The impact of aromatase inhibitors on sexual functioning: Current knowledge and future research directions. Breast.
  39. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.